Glioblastoma caseload to head past 66,000 by 2035

In 2025, China accounted for 45% of cases in the eight major markets.

Diagnosed glioblastoma (GBM) cases in the eight major markets (8MM) are set to increase at an annual growth rate (AGR) of 0.81% to over 66,000 in 2035 from over 61,000 in 2025.

These countries include the United States, France, Germany, Italy, Spain, the United Kingdom, Japan, and China.

According to GlobalData, China will have the highest number of cases, with 29,000, whereas Japan will have the fewest diagnosed cases, with 1,800.

In 2025, China accounted for 45% of all diagnosed GBM in the 8MM due to its large population.

“Further research into targeted chemotherapy and increased focus on screening may increase 5-year survival,” Casey Freimuth, senior epidemiologist at GlobalData, said.